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Objective: Gouty arthritis and familial Mediterranean fever share some clinical and patho-
logical features such as being classiﬁed as auto-inﬂammatory disease, association with
inﬂammasome, short-lived intermittent arthritis, and good response to colchicine and anti-
interleukin-1 treatments. As Mediterranean fever gene is the causative factor of familial
Mediterranean fever, we aimed to investigate the prevalence of Mediterranean fever gene
mutations and their effect on disease manifestations in Turkish gouty arthritis patients.
Methods: Ninety-seven patients diagnosed with primary gouty arthritis (93 M and 4 F, 54
[37–84] years) and 100 healthy controls (94 M and 6 F, 57 [37–86] years) were included in
the  study. All subjects were genotyped for the Mediterranean fever gene variations. Number
of  gout attacks, diuretic use, history of nephrolithiasis and presence of tophus were also
recorded.
Results: The carriage rate of Mediterranean fever mutations for patients and controls was
22.7%  (n = 22) and 24% (n = 24), respectively. The comparison of the patient and control groups
yielded no signiﬁcant difference in terms of the Mediterranean fever mutations’ carriage rate
(p  = 0.87). The allelic frequencies of the Mediterranean fever mutations in patients were 11.9%
(n  = 23) and 14% (n = 28) in controls (p = 0.55). The presence of Mediterranean fever variants
did  not show any association with clinical features of gouty arthritis. The subgroup analysis
of  patients revealed that gouty arthritis patients with mutations had similar frequencies
of  tophus, history of nephrolithiasis and podagra compared to the ones without mutations
(p  > 0.05).
Conclusions: This study does not provide support for a major role of Mediterranean fevermutations in Turkish gouty arthritis patients.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: ismailsari35@gmail.com (I. Sari).
ttp://dx.doi.org/10.1016/j.rbre.2014.10.008
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Existe  uma  relac¸ão entre  a  artrite  gotosa  e  as  mutac¸ões  genéticas  da  febre
familiar  do  Mediterrâneo?
Palavras-chave:
Artrite gotosa
Proteína MEFV
Febre familiar do Mediterrâneo
r  e  s  u  m  o
Objetivo: A artrite gostosa e a febre familiar do Mediterrâneo (FFM) compartilham algumas
características clínicas e patológicas, como ser classiﬁcada como uma doenc¸a autoimune
inﬂamatória, ter associac¸ão com o inﬂamassoma, manifestar artrite intermitente de curta
durac¸ão  e boa resposta a tratamentos com colchicina e anti-interleucina-1. Como o gene da
febre  familiar do Mediterrâneo (MEFV) é o fator causador da FFM, este estudo teve como obje-
tivo  investigar a prevalência de mutac¸ões do gene MEFV e seu efeito sobre as manifestac¸ões
da  doenc¸a em pacientes turcos com artrite gotosa.
Métodos: Foram incluídos no estudo 97 pacientes com diagnóstico de artrite gotosa primária
(93 M e 4 F; 54 [37-84] anos) e 100 controles saudáveis (94 M e 6 F; 57 [37-86] anos). Todos os
indivíduos foram submetidos à análise do genótipo à procura de variac¸ões no MEFV. Também
foi  registrado o número de crises de gota, o uso de diuréticos e a história de nefrolitíase e
presenc¸a  de tofos.
Resultados: A frequência de portadores de mutac¸ões no MEFV em pacientes e controles
foi  de 22,7% (n = 22) e 24% (n = 24), respectivamente. A comparac¸ão entre os pacientes e
os  controles não produziu diferenc¸a estatisticamente signiﬁcativa em termos de frequên-
cia  de portadores de mutac¸ões no MEFV (p = 0,87). As frequências alélicas de mutac¸ões no
MEFV nos pacientes foram de 11,9% (n = 23) e 14% (n = 28) nos controles (p = 0,55). A presenc¸a
de  variantes do MEFV não mostrou qualquer associac¸ão com as características clínicas da
artrite gotosa. A análise por subgrupos de pacientes revelou que aqueles com artrite gotosa
com mutac¸ões tinham frequências semelhantes de tofo, história de nefrolitíase e podogra
em  comparac¸ão com os indivíduos sem mutac¸ões (p > 0,05).
Conclusões: As mutac¸ões no gene MEFV não exercem um papel relevante em pacientes turcos
com artrite gotosa.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Gouty arthritis is one of the most frequently observed inﬂam-
matory arthritis in the world. Although its epidemiology
shows signiﬁcant ethnical variations, it is affecting at least
1–2% of men  in the western world.1 Gouty arthritis has some
classical clinical ﬁndings such as acute painful attacks of
arthritis in the joints (especially the ﬁrst metatarsal joint of the
foot), mono-articular involvement and intermittent pattern.2
It is caused by the deposition of monosodium urate mono-
hydrate (MSU) crystals in the joints. MSU  crystals induce a
variety of inﬂammatory cytokines particularly interleukin-1
(IL-1).3 In addition, recent reports revealed a major role for
inﬂammasome activity in the development of gout attacks.3
On the other hand, familial Mediterranean fever (FMF) is the
most commonly seen periodic fever syndrome.4 FMF is caused
by the mutations (single substitutions) in the MEditerranean
FeVer (MEFV) gene at the short arm of the 16th chromosome.4
This gene encodes a protein called pyrin. Under normal
circumstances, pyrin limits the activation of the NLRP3-
inﬂammasome. It is presumed that the mutated pyrin protein
in FMF  is theoretically not able to suppress the inﬂamma-
some, and thus the inﬂammatory response develops.5 Both
gouty arthritis and FMF  share some clinical and pathogenic
mechanisms such as short-lived and intermittent arthritis,
association with inﬂammasome and response to colchicine
and anti-IL-1 therapies.3,6 To the best of our knowledge, therehas been no previous study about the association between
MEFV gene mutations and gouty arthritis. In this study, we
aimed to investigate the prevalence of MEFV gene mutations
and their effect on disease manifestations in Turkish gouty
arthritis patients.
Methods
Sample  size  calculation
The sample size was calculated by using the results of previous
studies that investigated the frequency of MEFV mutations in
patients with inﬂammatory rheumatic diseases and healthy
controls.7,8 According to the analysis, based on  ˛ = 0.05 and a
power of 80%, at least 89 subjects were needed per group.
Patients  and  controls
Ninety-seven unrelated patients diagnosed with primary
gouty arthritis were recruited from the outpatient clinic of
Gulhane Military School of Medicine Department of Rheuma-
tology (Ankara, Turkey). The clinical diagnosis of gout was
established by the revised American College of Rheumatology
classiﬁcation criteria.9 Patients were also questioned for the
presence of the Tel-Hashomer criteria for diagnosis of FMF.10
Sex, age, number of gout attacks, diuretic use, and history of
nephrolithiasis and presence of tophus were also collected.
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Table 1 – Distribution of the MEFV gene mutations in the
gouty arthritis and healthy control groups.
Gouty arthritis
patients, n = 97
Healthy controls,
n = 100
M694V/M694V 1
M694V/WT 4 2
M694V/R202Q 1
E148Q/E148Q 2
E148Q/WT 9 14
V726A/WT 1
R761H/WT 1 1
M680I/WT 1
A744S/WT 1 1
K695R/WT 1 1
R202Q/WT 2
R202Q/E230K 1
T267I/WT 1r e v b r a s r e u m a t o l
he control group included 100 unrelated healthy subjects
ithout any history of chronic diseases and was recruited
rom the blood donors and relatives of hospital staff. The study
as approved by the Ethics Committee and informed consent
as obtained from all the participants.
EFV  gene  mutation  analysis
 total of 197 specimens collected were analyzed for
he mutations of the MEFV gene. Genomic DNA from
hole blood samples was isolated with QIAamp DNA
lood Mini Kit (Qiagen, Hilden, Germany) according to
he manufacturer’s instructions. Both exon 2 and exon
0 of the MEFV gene were ampliﬁed by polymerase
hain reaction (PCR) using the following primers: 5′-
TGGGACAGCTTCATCATTTTG-3′and 5′-CCTTCTCTCTGCGTT
GCTC-3′ (exon 2), 5′-TTACTGGGAGGTGGAGGTTG-3′, and 5′-
AGG AGCTGTGTTCTTCCC-TC-3′ (exon 10). PCR products
ere puriﬁed using a QIAquick PCR Puriﬁcation Kit (Qia-
en). Puriﬁed PCR amplicons were bidirectionally ﬂuorescence
equenced using ABI BigDye Terminator version 1.1 Cycle
equencing Kit (Applied Biosystems) and run on a ABI 3100
utomated sequencer (Applied Biosystems).
tatistical  analysis
esults were expressed as mean ± standard deviation (SD) and
roportions as percentages. A chi-square test or Fisher’s exact
est was used, when appropriate, to assess the difference
n the prevalence of MEFV variants between gouty arthritis
atients and healthy controls. Spearman’s rho test was used
o describe correlations. All p values were 2-tailed, and conﬁ-
ence intervals (CIs) were set at 95%. p-values less than 0.05
ere considered signiﬁcant. The statistical analysis was car-
ied out by using Statistical Package for the Social Science
SPSS), version 13.0 (SPSS Inc., Chicago, IL, USA).
esults
here were 97 gouty arthritis patients (93 male [M] and 4
emale [F], 54 [37–84] years) and 100 healthy controls (94 M
nd 6 F, 57 [37–86] years). The sex and age distributions were
ot different between the groups (p values are 0.75 and 0.09,
espectively). The median number of gout attacks of the
atients were 2 (1–40); 10.8% of the patients had tophus, 21.5%
ad renal stone history, 23.7% of the patients were receiving
iuretics and 18.3% had a history of alcohol intake.
There were 22 patients and 24 healthy controls that were
arrying at least one mutated MEFV allele. Exon 2 mutations
bserved in this study were E148Q, R202Q, E230K, T267I and
177I. The detected exon 10 mutations were M694V, M680I,
726A, R761H, A744S and K695R. Distribution of the muta-
ions in the patients and healthy controls are summarized in
able 1. The carriage rate of MEFV mutations for patients and
ontrols were 22.7% and 24%, respectively. The comparison of
he patient and control groups yielded no signiﬁcant differ-
nce in terms of the MEFV mutations carriage rate (p = 0.87;
5% CI = 0.57–1.57). The sub-group analysis revealed that 31
15.7%) subjects were carrying exon 2 and 16 (8.1%) wereT177I/WT 1
WT, wild type.
carrying at least one exon 10 mutations. The gouty arthritis
patients and controls did not show any signiﬁcance regarding
the carriage rate of exon 2 (12 [12.4%] vs.  19 [19%]; p = 0.24; 95%
CI = 0.33–1.27, respectively) and exon 10 (10 [10.3%] vs. 6 [6%];
p = 0.31; 95% CI = 0.65–4.55, respectively) mutations (Table 2).
The allelic frequencies of the MEFV mutations in patients
were 11.9% (n = 23) and 14% (n = 28) in controls. The allele fre-
quencies did not show any signiﬁcance when the patients
and controls were compared (p = 0.55; 95% CI = 0.51–1.42). Total
exon 2 and exon 10 mutations were observed in 34 (8.6%) and
17 (4.3%) subjects respectively. The gouty arthritis patients and
controls did not show any signiﬁcance regarding the distribu-
tion of exon 2 (12 [6.2%] vs. 22 [11%]; p = 0.11; 95% CI = 0.28–1.1,
respectively) and exon 10 (11 [5.7%] vs. 6 [3%]); p = 0.22; 95%
CI = 0.71–5.01, respectively) mutations (Table 2).
When we analyzed E148Q separately, neither carriage rate
nor allelic frequencies were different between gouty arthri-
tis patients and healthy controls (p = 0.2; 95% CI = 0.23–1.28;
p = 0.11; 95% CI = 0.21–1.12, respectively). Similarly, M694V
mutations were not differed signiﬁcantly between patients
and controls (carriage rate p = 0.49; 95% CI = 0.41–7.56 and allele
frequency p = 0.33; 95% CI = 0.52–8.5).
The subgroup analysis of gouty arthritis patients regarding
their MEFV gene mutation status revealed that gouty arthri-
tis patients with mutations had similar frequencies of tophus
(11.3% vs.  9.1%, respectively, p = 1), history of nephrolithia-
sis (22.5% vs.  18.2%, respectively, p = 0.77) and podagra (42.3%
vs. 45.5, respectively, p = 0.81) compared to the ones without
mutations. In addition the number of gout attacks were also
similar between the patients with and without mutations (2
[1–8] vs. 2 [1–40], respectively, p = 0.38).
The presence of MEFV mutations and the presence of
tophus, history of nephrolithiasis, diuretic usage and number
of attacks did not show any correlation (p = 0.61; 0.73; 0.81 and
0.38, respectively).Discussion
In this study we showed that both the carriage rate and
allelic frequencies of MEFV gene mutations were not different
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Table 2 – Allele frequencies and carriage rates of MEFV variants in patients with gouty arthritis as compared with healthy
controls.
Gouty arthritis patients, n = 97 Healthy controls, n = 100 p-value (95% CI)
Carriage rate, %
Total exon 2 variants 12 (12.4) 19 (19) 0.24 (0.33–1.27)
Total exon 10 variants 10 (10.3) 6 (6) 0.31 (0.65–4.55)
Total MEFV variants 22 (22.7) 24 (24) 0.87 (0.57–1.57)
Allele frequency, %
Total exon 2 variants 12 (6.2) 22 (11) 0.11 (0.28–1.1)
rTotal exon 10 variants 11 (5.7)
Total MEFV variants 23 (11.9)
between the gouty arthritis patients and healthy controls. Fur-
thermore the presence of MEFV variants did not show any
association with clinical features of gouty arthritis. In addi-
tion, the severity of the gout did not show any difference
between the patients with and without MEFV mutations.
Gouty arthritis is one of the commonest forms of inﬂam-
matory arthropathy in the elderly population. MSU  crystals
trigger the inﬂammatory cascade, which ultimately result in
pain and inﬂammation. In recent years several reports showed
an association between NLRP3 inﬂammasome and gouty
arthritis.3 It is hypothesized that MSU  crystals increase NLRP3-
induced IL-1 and dysregulated production of the cytokine
plays an important role in the clinical features of gout.3
Recently gout is classiﬁed as a form of auto-inﬂammatory
diseases.11
FMF  is a hereditary auto-inﬂammatory disorder character-
ized by acute attacks of fever and serosal inﬂammation. It is
prevalent among certain ethnic groups such as Jews, Arme-
nians, Turks, and Arabs.4 FMF  is caused by mutations in the
MEFV gene, which encodes the pyrin protein. Mutant pyrin is
associated with uncontrolled inﬂammatory cascade, probably
by dysregulated inﬂammasome function and excessive IL-1
production.5
In recent years there is a considerable interest regarding
MEFV gene mutations and its association with different
inﬂammatory diseases. In this respect MEFV mutations found
to be increased in ankylosing spondylitis,12 juvenile idio-
pathic arthritis,13 inﬂammatory bowel disease,8 palindromic
rheumatism,14 Behcet’s disease,7 polyarteritis nodosa15 and
Schoenlein–Henoch purpura.16 Furthermore it was shown that
these mutations were associated with severe disease prog-
nosis in other inﬂammatory syndromes such as rheumatoid
arthritis.17
Because of the similarities between gout and FMF (auto-
inﬂammatory disease, short-lived intermittent arthritis, and
good response to colchicine and anti-IL-1 treatments) we
have undertaken this study to ﬁnd out whether there is a
relation with MEFV mutations, causative gene of FMF,  in gouty
patients. We  revealed that carriage rate and allelic frequencies
were not different between the patient and control groups. In
literature, a case of a Japanese patient with atypical symptoms
of gouty arthritis was reported to carry heterozygous E148Q
mutation.18 To the best of our knowledge there is no other
report regarding the association of MEFV and gout. It is known
that certain MEFV mutations have severe clinical outcome
such as the association of amyloidosis with M694V genotype
in FMF.19 On the other hand, some reports emphasized the6  (3) 0.22 (0.71–5.01)
28  (14) 0.55 (0.51–1.42)
over-representation of E148Q in several inﬂammatory
disorders.14 In our sub-group analysis neither M694V alone
nor total exon 10 mutations were different in the study group.
Similarly E148Q alone and total exon 2 mutations were also
not different between the patient and control groups. We
also did not show any association with MEFV mutations and
disease phenotype such as nephrolithiasis and tophus. In
addition our subgroup analysis revealed that the number of
attacks, presence of tophus, history of nephrolithiasis and
podagra were not different between the patients with and
without mutations. Based on the latter ﬁnding, someone may
suggest that the presence of mutations in the gouty arthritis
patients may not have an effect on disease severity.
This study has some limitations such as small sample size
of total 197 cases and cross-sectional collection of data. In con-
clusion, despite these limitations, the results presented in this
study do not provide support for a major role of MEFV muta-
tions in Turkish gouty arthritis patients. Further replication
studies in different populations with larger number of patients
are needed to conﬁrm our results.
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